Moexipril Hydrochloride
Grundinformationen
- CAS
82586-52-5- Standard-SMILES
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl- InChIKey
JXRAXHBVZQZSIC-JKVLGAQCSA-N- Summenformel
- C27H35ClN2O7
- Durchschnittliche Molmasse
- 535 g/mol
- Monoisotopische Masse
- 534,2132792
Namen und Bezeichner
- Bevorzugter Name
- Moexipril Hydrochloride
- IUPAC
- (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride
- Englischer Name
- Moexipril hydrochloride
- Summenformel
- C27H35ClN2O7
- Molmasse
- 535.03
Namen und Synonyme
MOEXIPRIL HYDROCHLORIDE82586-52-5Moexipril HCLSPM 925CI 925DTXSID7044267RS-10085-197SPM-925Q1UMG3UH45DTXCID50242673-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, monohydrochloride, (3S-(2(R*(R*)),3R*))-(3S)-2-((2S)-N-((1S)-1-Carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester, monohydrochloride
Weitere Namen anzeigen
PerdixRS-10085FempressMoexipril HCl - Bio-X ?Moexipril HCl (RS-10085)
(3S)-2-[(2S)-N-[(1S)-1-Carboxy-3-phenylpropyl]alanyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester, monohydrochlorideRefChem:57153617-363-1UnivascMoexipril hydrochloride [USAN]CI-925Moexipril (hydrochloride)(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 114 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 12
- Schwere Atome
- 37
- Formalladung
- 0
- Komplexität
- 742
Physikochemische Eigenschaften
- Schmelzpunkt
- 141 · 141-1610C
- storage temp.
- 2 · 2-8°C
- Löslichkeit
- 2 O: · H2O: soluble32mg/mL
- Aggregatzustand
- powder
- Farbe
- White to off-white
- Wasserlöslichkeit
- 2 O: · H2O: 32mg/mL
- InChIKey
- JXRAXHBVZQZSIC-JKVLGAQCSA-N
- SMILES
- Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3cc(OC)c(OC)cc3C[C@H]2C(O)=O
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H400 (95.1%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]
P273, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
Gefahrenhinweise
Hazard Classes and CategoriesAquatic Acute 1 (95.1%)
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Moexipril hydrochloride
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation；Because no information is available on the use of moexipril during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Relevant published information was not found as of the revision date.
Sicherheitsdaten
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
MOEXIPRIL HYDROCHLORIDE
Angiotensin Converting Enzyme Inhibitor [EPC]; Angiotensin-converting Enzyme Inhibitors [MoA]
MeSH Pharmacological Classification
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Anwendungen
BeschreibungMoexipril hydrochloride is a novel ACE inhibitor first marketed in the U.S.A. for the treatment of hypertension as a monotherapy and as a second-line therapy in combination with diuretics or calcium antagonists. Like other ACE inhibitors, moexipril is a prodrug that is converted in the liver to its diacid moexiprilat which is the active agent. Moexipril displays a higher in vitro inhibitory potency to ACE than enalapril although its effectiveness in reduction of blood pressure in hypertensive patients is similar to that seen with enalapril. It is orally active with a rapid onset and prolonged duration of action. Excellent tolerability has been reported. Moexipril is distinguished by its lower cost than other marketed ACE inhibitors.
VerwendenAngiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of quinapril
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
1
Notizen zur Verbindung
Wird geladen…